Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

13.60
+0.81506.38%
Post-market: 13.52-0.0750-0.55%19:51 EDT
Volume:4.12M
Turnover:54.96M
Market Cap:1.41B
PE:-2.61
High:13.71
Open:12.82
Low:12.73
Close:12.78
Loading ...

Intellia Therapeutics price target lowered to $54 from $74 at Canaccord

TIPRANKS
·
03 Jun

Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study

TIPRANKS
·
30 May

Intellia Therapeutics: Positive Outlook and Strong Enrollment Support Buy Rating

TIPRANKS
·
30 May

Evercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
30 May

Intellia's Stock Drops Following Adverse Event in Nex-Z Trial

Dow Jones
·
29 May

Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating

TIPRANKS
·
29 May

Intellia Therapeutics price target lowered to $39 from $43 at BofA

TIPRANKS
·
29 May

Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well

MT Newswires Live
·
29 May

TD Cowen Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
29 May

Intellia Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
29 May

Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating

MT Newswires Live
·
29 May

J.P. Morgan Remains a Hold on Intellia Therapeutics (NTLA)

TIPRANKS
·
29 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Savara (SVRA) and Intellia Therapeutics (NTLA)

TIPRANKS
·
29 May

Intellia Therapeutics Updates on Phase 3 Study Progress

TIPRANKS
·
29 May

Intellia Therapeutics’ ATTR-PN Trial Shows Promising Long-Term Efficacy, Justifying Buy Rating

TIPRANKS
·
21 May

Intellia Therapeutics Price Target Maintained With a $10.00/Share by Wedbush

Dow Jones
·
19 May

Sector Update: Health Care Stocks Steady-to-Lower Pre-Bell Monday

MT Newswires Live
·
19 May

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday After Moody's Downgrades US Credit Rating

MT Newswires Live
·
19 May

Top Premarket Gainers

MT Newswires Live
·
19 May

TD Cowen Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
19 May